Angela – Ireland: Alopecia Universalis (LDN, low dose naltrexone)
Angela – Ireland: Alopecia Universalis (LDN, low dose naltrexone) from LDN Research Trust on Vimeo. Angela from Ireland shares her Alopecia and LDN Story on the LDN Radio Show with Linda Elsegood. Angela first noticed her loss of her when she ran her hand through her hair and found a small patch of hair was […]
Psychopharmacologic Therapies for Irritable Bowel Syndrome (Abstract)
Psychopharmacologic Therapies for Irritable Bowel Syndrome (Abstract) Gastroenterol Clin North Am Epub 01 July 2021 https://pubmed.ncbi.nlm.nih.gov/34304793/ Psychopharmacologic therapies are beneficial in reducing symptoms when treating irritable bowel syndrome (IBS) and other disorders of gut-brain interaction (DGBI). Noradrenaline, serotonin, and dopamine are neurotransmitters of key importance in psychopharmacology and pain-reduction mechanisms. The first-line (tricyclic antidepressants, serotonin […]
Katie gives an update on taking LDN for Fibromyalgia, Interstitial Cystitis, GERD, IBS(LDN, low dose naltrexone)
Katie gives an update on taking LDN for Fibromyalgia, Interstitial Cystitis, GERD, IBS (LDN, low dose naltrexone) from LDN Research Trust on Vimeo. Katie from the US gives as an update on taking Low Dose Naltrexone (LDN) for Fibromyalgia, Interstitial Cystitis, GERD, IBS. Katie suffers multiple autoimmune conditions including Fibromyalgia, which caused pain, extreme fatigue, […]
Berglind from Iceland talk about LDN and Hypermobile Ehlers Danlos, IBS, Allergies (LDN, low-dose Naltrexone)
Berglind from Iceland talk about LDN and Hypermobile Ehlers Danlos, IBS, Allergies (LDN, low-dose Naltrexone) from LDN Research Trust on Vimeo. Berglind had suffered many years with her Hypermobile Ehlers Danlos, IBS, and allergies. At long last she found out about LDN on Facebook, and her doctor was LDN knowledgeable. He prescribed it for her. […]
Low-Dose Naltrexone for Pruritus in Systemic Sclerosis (Abstract)
Low-Dose Naltrexone for Pruritus in Systemic Sclerosis Int J Rheumatol 12 September 2011 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171757/ Pruritus is a common symptom in systemic sclerosis (SSc), an autoimmune disease which causes fibrosis and vasculopathy in skin, lung, and gastrointestinal tract (GIT). Unfortunately, pruritus has limited treatment options in this disease. Pilot trials of low-dose naltrexone hydrochloride (LDN) for […]
Low-Dose Naltrexone (LDN) Treatment for Crohn’s Disease (CD)… (Abstract)
Low-Dose Naltrexone (LDN) Treatment for Crohn’s Disease (CD): A Tertiary Care Center Experience Am J Gastroenterol October 2011 https://journals.lww.com/ajg/Fulltext/2011/10002/Low_Dose_Naltrexone__LDN__Treatment_for_Crohn_s.1223.aspx Purpose: In recent years, there have been many advances in the treatment of CD therapy; including the development of anti-tumor necrosis factor alpha antibodies. However, despite these advances, about 20% of patients do not respond to […]
Safety and tolerability of Low-Dose Naltrexone therapy in children with moderate to severe Crohn’s disease… (Abstract)
Safety and tolerability of Low-Dose Naltrexone therapy in children with moderate to severe Crohn’s disease: a pilot study J Clin Gastroenterol 01 April 2014 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586944/ Background There is an unmet need for safe and effective medicines to treat children with Crohn’s disease. Recently, investigations have shown an association between endogenous opioid peptides and inflammatory cells. […]
Immunological changes in IBD patients responding to low-dose naltrexone treatment (Abstract)
P388 Immunological changes in IBD patients responding to low-dose naltrexone treatment J Crohn’s and Colitis 01 February 2012 https://academic.oup.com/ecco-jcc/article/6/Supplement_1/S164/369091 LDN treatment was successful in part of the IBD patients not responding to other medication. Whether the CD16+ CD62-L+ CD14 monocyte population is a direct target of the opioid growth factor opioid growth factor receptor signaling […]
Low-Dose Naltrexone Therapy Improves Active Ulcerative Colitis (Abstract)
P-015 YI Low-Dose Naltrexone Therapy Improves Active Ulcerative Colitis Inflam Bowel Dis 01 December 2013 https://academic.oup.com/ibdjournal/search-results?page=1&q=Low-Dose%20Naltrexone%20Therapy%20Improves%20Active%20Ulcerative%20Colitis&fl_SiteID=6136&SearchSourceType=1&allJournals=1 Low-dose naltrexone (LDN) has shown promise in several clinical studies as a safe and effective treatment for Crohn’s disease (CD). Naltrexone is an opioid receptor antagonist. It acts as a competitive antagonist at several opioid receptor sites, showing the highest […]
Low dose naltrexone in therapy resistant IBD, a case series (Abstract)
P418 Low dose naltrexone in therapy resistant IBD, a case series J Crohn’s and Colitis February 2014 https://www.gastrojournal.org/article/S0016-5085(14)61660-7/pdf Introduction: Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are chronic relapsing bowel disorders. Several established drug therapies exist, but some patients become resistant to these. For these patients, new treatments are urgently […]